Cancer Trials available at Berks Hematology Oncology Associates
Breast
Breast
- SCRI BRE 161 Phase I/II Trial of Amrubicin as second or third-line treatment for patients with HER2-Negative metastatic breast cancer.
- Millennium C05013 Phase 2 study of RCHOP +/- Velcade in previously untreated non-germinal center B-cell like DLBC lymphoma.
- SCRI LYM 37 Phase 2 study of Rituximab +/- Bevacizumab in FOLLICULAR low-grade non-Hodgkins lymphoma.
- Celgene - Connect MM multiple myeloma registry for newly diagnosed symptomatic MM.
- ImClone Phase 3 study of IMC-1121B & Best supportive Care versus Placebo & BSC for metastatic gastric or GE Junction adenocarcinoma following progression after 1st line therapy.
- Celgene Connect CLL Chronic Lymphocytic Leukemia Disease Registry for patients initiated on therapy for CLL ( any line of therapy).
- Celgene CC5013-CLL-008 Phase 3 Lenalidomide versus Chlorambucil as 1st line therapy For previously untreated elderly patients with B-cell CLL. (Opening 12/13/10).
- Sanofi-Aventis / Bi-Par Sciences ECLIPSE study Phase 3 trial of Gemzar/ Carboplatin with/without BSI-201 (PARP Inhibitor) in patients with previously untreated advanced squamous cell lung cancer.
- Helsinn Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Anamorelin in patients with NSCLC cachexia.
- Amgen Phase 3 double blind study of Pegfilgrastim administered to subjects 1st line locally advanced or metastatic CRC treated with Bevacizumab and either FOLFOX or FOLFIRI (opening 3/30).
- Merck V212-011- Phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancies. (VZV vaccine).
